| Innovative Molecules–Life Sciences Partners: investment, 202106 financing round Series A totalling €20m incl lead investor LSP |
2021-06-07 |
| Innovative Molecules–SEVERAL: investment, 202106 financing round Series A €20m led by LSP |
2021-06-07 |
| MedXCell–PERSON: investment, 202106 financing round Series A totalling CHF5.3m incl new + lead investor Anh Nguyen |
2021-06-04 |
| MedXCell–SEVERAL: investment, 202106 financing round Series A CHF5.3m led by Anh Nguyen + incl other private investors |
2021-06-04 |
| Corat Therapeutics–Germany (govt): grant, 202106– up to €7m grant from BMBF from Covid-19 drug programme |
2021-06-03 |
| Corat Therapeutics–Lower Saxony (govt): investment, 202106 3rd financing round totalling €5.7m? incl existing investor NBank Capital |
2021-06-03 |
| Corat Therapeutics–OTHER: investment, 202106 3rd financing round totalling €5.7m? incl private investors from Braunschweig |
2021-06-03 |
| Corat Therapeutics–SEVERAL: investment, 202106 3rd financing round €5.7m? from NBank Capital + private investors |
2021-06-03 |
| AstraZeneca–Celonis: management execution software, 202106 supply existent customer AstraZeneca |
2021-06-02 |
| AstraZeneca–Proteros: small-molecule cancer drugs, 202106– collab RnD + license agreem with research funding + $62m milestones + royalties |
2021-06-02 |
| Celonis–Arena Holdings: investment, 202106 financing round Series D totalling $1b incl existing + co-investor Arena Holdings |
2021-06-02 |
| Celonis–Durable Capital: investment, 202106 financing round Series D totalling $1b incl new + co-lead investor Durable Capital Partners LP |
2021-06-02 |
| Celonis–Franklin Templeton: investment, 202106 financing round Series D totalling $1b incl new + co-investor Franklin Templeton |
2021-06-02 |
| Celonis–SEVERAL: investment, 202106 financing round Series D $1b co-led by Durable Capital Partners + T Rowe Price |
2021-06-02 |
| Celonis–Splunk Ventures: investment, 202106 financing round Series D totalling $1b incl new + co-investor Splunk Ventures |
2021-06-02 |
| Celonis–T Rowe Price: investment, 202106 financing round Series D totalling $1b incl new + co-lead investor funds+accounts managed by T Rowe Price |
2021-06-02 |
| Constellation–Centerview Partners: financial services, 202106 supply service Centerview Partners is financial advisor for acquisition by MorphoSys |
2021-06-02 |
| Constellation–MorphoSys: investment, 202106–202107 acquisition cash tender offer $1.7b at $34/share by MorphoSys |
2021-06-02 |
| Constellation–Wachtell Lipton: legal services, 202106 supply service Wachtell Lipton is legal advisor regarding acquisition by MorphoSys |
2021-06-02 |
| Danaher–Celonis: management execution software, 202106 supply existent customer Danaher Corp |
2021-06-02 |
| Gilde Investment–LifeSci: public relations, 202106 supply service existent LifeSci Advisors is media contact for Gilde Healthcare |
2021-06-02 |
| GoSilico–Danaher: investment, 202106 acquisition of GoSilico GmbH by Cytiva |
2021-06-02 |
| GSK–Celonis: management execution software, 202106 supply existent customer GSK |
2021-06-02 |
| L’Oréal–Celonis: management execution software, 202106 supply existent customer L’Oréal |
2021-06-02 |
| MorphoSys–Goldman Sachs: financial services, 202106 supply service GS Bank Europe SA is financial advisor with regard to acquisition of Constellation |
2021-06-02 |
| MorphoSys–Royalty Pharma: credit, 202106– up to $350m development funding bonds over 1-year period |
2021-06-02 |
| MorphoSys–Royalty Pharma: investment, 202106–202107 capital increase $100m excl subscription rights resulting in 3.9% shareholding for Royalty Pharma |
2021-06-02 |
| MorphoSys–Skadden Arps: legal services, 202106 supply service Skadden Arps Slate Meagher & Flom is legal advisor for acquisition of Constellation |
2021-06-02 |
| Pfizer–Celonis: management execution software, 202106 supply existent customer Pfizer |
2021-06-02 |
| Royalty Pharma–Goodwin Procter: legal services, 202106 supply service Goodwin is legal advisor regarding royalty + licensing agreem with MorphoSys |
2021-06-02 |
| Royalty Pharma–MorphoSys: guselkumab + otilimab et al, 202106– acquisition royalty/milestone rights $1.425b upfront + $150m milestones by Royalty |
2021-06-02 |
| Siemens–Celonis: management execution software, 202106 supply existent customer Siemens |
2021-06-02 |
| BioVersys–CARB-X: grant, 202106– award non-dilutive funding $4.35m for antibiotics RnD with possibility for additional $10.98 milestone-related |
2021-06-01 |
| Inovedis–High-Tech Gründerfonds: investment, 202106 seed financing round totalling €1.8m incl lead investor HTGF |
2021-06-01 |
| Inovedis–SEVERAL: investment, 202106 seed financing round €1.8m led by HTGF |
2021-06-01 |
| Araxa Biosciences–Velabs Therapeutics: investment, 202105 acquisition of Araxa by Velabs company renamed Veraxa Biotech GmbH |
2021-05-31 |
| Ada Health–Bayer: investment, 202105 financing round Series B totalling $90m incl lead investor Leaps by Bayer |
2021-05-27 |
| Ada Health–F4: investment, 202105 financing round Series B totalling $90m incl co-investor F4 |
2021-05-27 |
| Ada Health–Inteligo Bank: investment, 202105 financing round Series B totalling $90m incl co-investor Inteligo Bank |
2021-05-27 |
| Ada Health–Mutschler Ventures: investment, 202105 financing round Series B totalling $90m incl co-investor Mutschler Ventures |
2021-05-27 |
| Ada Health–Samsung: investment, 202105 financing round Series B totalling $90m incl co-investor Samsung Catalyst Fund |
2021-05-27 |
| Ada Health–SEVERAL: investment, 202105 financing round Series B $90m led by Leaps by Bayer |
2021-05-27 |
| Ada Health–Vitruvian Partners: investment, 202105 financing round Series B totalling $90m incl co-investor Vitruvian Partners |
2021-05-27 |
| BrainRepair–PERSON: investment, 202105 investment Metin Colpan acquires 5% of shares of BrainRepair worth €15m |
2021-05-27 |
| Origin.bio–Acequia Capital: investment, 202105 financing round totalling $15m incl new + co-investor Acequia Capital |
2021-05-26 |
| Origin.bio–BY Capital: investment, 202105 financing round totalling $15m incl existing + co-investor BlueYard Capital |
2021-05-26 |
| Origin.bio–EQT: investment, 202105 financing round totalling $15m incl lead investor EQT Ventures |
2021-05-26 |
| Origin.bio–Inventures: investment, 202105 financing round totalling $15m incl new + co-investor Inventures |
2021-05-26 |
| Origin.bio–PERSON: investment, 202105 financing round totalling $15m incl new + co-investor Charlie Songhurst |
2021-05-26 |
| Origin.bio–PERSON: investment, 202105 financing round totalling $15m incl new + co-investor Sten Tamkivi |
2021-05-26 |
| Origin.bio–PERSON: investment, 202105 financing round totalling $15m incl new + co-investor Taavet Hinrikus |
2021-05-26 |
| Origin.bio–SEVERAL: investment, 202105 financing round $15m led by EQT Ventures |
2021-05-26 |
| Haya Therapeutics–4See Ventures: investment, 202105 seed financing round totalling CHF18m incl co-investor 4See Ventures |
2021-05-20 |
| Haya Therapeutics–Apollo Health Ventures: investment, 202105 seed financing round totalling CHF18m incl co-investor Apollo HV |
2021-05-20 |
| Haya Therapeutics–Bernina BioInvest: investment, 202105 seed financing round totalling CHF18m incl co-investor Bernina BioInvest |
2021-05-20 |
| Haya Therapeutics–Bioscribe: public relations, 202105 service existent by Bioscribe |
2021-05-20 |
| Haya Therapeutics–Broadview Ventures: investment, 202105 seed financing round totalling CHF18m incl lead investor Broadview Ventures |
2021-05-20 |
| Haya Therapeutics–Schroders: investment, 202105 seed financing round totalling CHF18m incl co-investor Schroder Adveq |
2021-05-20 |
| Haya Therapeutics–SEVERAL: investment, 202105 seed financing round CHF18m led by Broadview Ventures |
2021-05-20 |
| Haya Therapeutics–Univ Lausanne: RNA-targeting drug, 202105 license excl existent for lncRNA Wisper targeting drug from CHUV |
2021-05-20 |
| Haya Therapeutics–Viva Biotech: investment, 202105 seed financing round totalling CHF18m incl co-investor Viva BioInnovator |
2021-05-20 |
| Numab–BlackRock: investment, 202105 financing round Series C totalling CHF100m incl new + co-investor funds/accounts managed by BlackRock |
2021-05-20 |
| Numab–BVF Partners: investment, 202105 financing round Series C totalling CHF100m incl new + co-investor BVF Partners LP |
2021-05-20 |
| Numab–Cormorant Asset Management: investment, 202105 financing round Series C totalling CHF100m incl new + co-investor Cormorant AM |
2021-05-20 |
| Numab–Forbion: investment, 202105 financing round Series C totalling CHF100m incl new + co-investor Forbion Growth Opportunities Fund |
2021-05-20 |
| Numab–HBM: investment, 202105 financing round Series C totalling CHF100m incl new + co-lead investor HBM Partners |
2021-05-20 |
| Numab–Novo Group: investment, 202105 financing round Series C totalling CHF100m incl new + co-lead investor Novo Holdings |
2021-05-20 |
| Numab–Octagon Capital: investment, 202105 financing round Series C totalling CHF100m incl new + co-investor Octagon Capital Advisors |
2021-05-20 |
| Numab–RTW Investments: investment, 202105 financing round Series C totalling CHF100m incl new + co-investor RTW investments LP |
2021-05-20 |
| Numab–SEVERAL: investment, 202105 financing round Series C CHF100m co-led by new investors Novo Holdings + HBM Partners |
2021-05-20 |
| Swixx Biopharma–HBM: investment, 202105– capital increase totalling €45m incl €5m from existing investor HBM Healthcare Investments |
2021-05-20 |
| Swixx Biopharma–Mérieux: investment, 202105– capital increase totalling €45m incl €40m for minority share from new investor MxEP |
2021-05-20 |
| Swixx Biopharma–SEVERAL: investment, 202105– capital increase €45m with €40m from new investor MxEP + €5m from existing investor HBM |
2021-05-20 |
| Nanoscribe–Cellink: investment, 202105 acquisition 100% of Nanoscribe Holding for preliminary €36.9m with €24.7m cash + €12.2m in Series B shares |
2021-05-19 |
| Hummingbird Bioscience–Bellevue: investment, 202105 financing round Series C totalling $125m incl new + co-investor Pureos Bioventures |
2021-05-18 |
| Hummingbird Bioscience–SEVERAL: investment, 202105 financing round Series C $125m led by Novo Holdings |
2021-05-18 |
| Immunodiagnostic Systems–PerkinElmer: investment, 202105– recommended all cash offer £110m by PerkinElmer ANNOUNCED |
2021-05-17 |
| Soteria Biotherapeutics–Merck (DE): investment, 202105 financing round Series A totalling $42m incl co-investor M Ventures |
2021-05-17 |
| Soteria Biotherapeutics–Novartis: investment, 202105 financing round Series A totalling $42m incl co-investor Novartis Venture Fund |
2021-05-17 |
| Soteria Biotherapeutics–Roche: investment, 202105 financing round Series A totalling $42m incl co-lead investor Roche Venture Fund |
2021-05-17 |
| Soteria Biotherapeutics–SEVERAL: investment, 202105 financing round Series A $42m co-led by Roche Venture Fund + 5AM Ventures |
2021-05-17 |
| Flare Therapeutics–Nextech: investment, 202105 financing round Series A totalling $82m incl co-investor Nextech Invest |
2021-05-13 |
| Flare Therapeutics–SEVERAL: investment, 202105 financing round Series A $82m led by Third Rock Ventures |
2021-05-13 |
| Biocatalysts Ltd–BRAIN Biotech: investment, 202105 acquisition addit 16.7% for £3.9m bringing total to 82.2% with 2 put options excercised |
2021-05-12 |
| AMSilk–Cargill: investment, 202105 financing round Series C totalling €29m incl new + co-investor Cargill |
2021-05-11 |
| AMSilk–ER Capital Holdings: investment, 202105 financing round Series C totalling €29m incl new + co-investor ER Capital Holdings |
2021-05-11 |
| AMSilk–MIG Fonds: investment, 202105 financing round Series C totalling €29m incl existing + co-investor MIG Verwaltungs AG |
2021-05-11 |
| AMSilk–Novo Group: investment, 202105 financing round Series C totalling €29m incl new + lead investor Novo Growth |
2021-05-11 |
| AMSilk–SEVERAL: investment, 202105 financing round Series C €29m led by Novo Growth with Cargill + ER Capital Holdings + MIG AG + Athos KG |
2021-05-11 |
| AMSilk–Strüngmann Group: investment, 202105 financing round Series C totalling €29m incl existing + co-investor Athos KG |
2021-05-11 |
| Abingworth–SEVERAL: investment, 202105 final closing at $582m of Abingworth Clinical Co-Development Fund 2 |
2021-05-10 |
| BioNTech–Singapore (govt): grant, 202105– support from Singapore EDB for planned mRNA-based vaccine + therapeutics manufacturing plant in Singapore |
2021-05-10 |
| Cellares–SEVERAL: investment, 202105 financing round Series B $82m led by Decheng Capital + Eclipse Ventures |
2021-05-05 |
| Cellares–Skyviews Life Science: investment, 202105 financing round Series B totalling $82m incl new + co-investor Skyviews Life Science |
2021-05-05 |
| Cytoki Pharma–+ND Capital: investment, 202105 financing round Series A totalling $45m incl co-investor +ND Captial |
2021-05-05 |
| Cytoki Pharma–SEVERAL: investment, 202105 financing round Series A $45m led by existing investor Lundbeckfonden Emerge |
2021-05-05 |
| Cytoki Pharma–Ysios Capital: investment, 202105 financing round Series A totalling $45m incl co-investor Ysios Capital |
2021-05-05 |
| APR Applied Pharma Research–Relief Therapeutics: investment, 202105– acquisition for CHF22m cash + CHF50m in shares binding term sheet signed |
2021-05-04 |
| ITM–Trophic Communications: public relations, 202105 service existent by Trophic Communications |
2021-05-04 |
| Labforward–Berlin (govt): investment, 202105 financing round Series B 2nd closing totalling >€3m incl existing + co-investor IBB Ventures |
2021-05-04 |
![[LSG] Life-Sciences-Germany.com - The Life Sciences Web Portal for German-speaking Europe](/images/basics/lsg-life-sciences-germany-portal-logo.svg){kind=logo}
1 2 3 ... 14 15 16 ... 44 45 46 
Date
![Picture [iito] LSE iitoLifeScience Life Sciences Mass Spec 120x120px](/banner/iito-business-intelligence-20230710-120-120-twitter-iitolifescience-germany-europe-mass-spec.jpg)
![Picture [LSE] Life-Sciences-Europe.com – The Business Web Portal 120x600px](/banner/iito-20150801-120-600-lse-life-sciences-europe-com.jpg)
